Table 5.
The assessment of the patient’s financial capability is established by classifying their household’s decile position based on comparing the cost of one month’s medication with the minimum daily wage of a worker
| # | Name of medicine | Affordable | Un- Affordable | Unavailable | |||
|---|---|---|---|---|---|---|---|
| Pakistan | Iran | Pakistan | Iran | Pakistan | Iran | ||
| 1 | Metformin 500 mg | 58(80.6%) | - | - | - | 14(19.4%) | 72(100%) |
| 2 | Metformin 850 mg | - | - | 12(16.7%) | - | 60(83.3%) | 72(100%) |
| 3 | Metformin 1000 mg | - | - | 51(70.8%) | - | 21(29.2%) | 72(100%) |
| 4 | Sitagliptin 50 mg | - | - | 25(347%) | - | 47(65.3%) | 72(100%) |
| 5 | Sitagliptin 100 mg | - | - | 16(22.2%) | - | 56(77.8%) | 72(100%) |
| 6 | Glimepiride 1 mg | - | - | 48(66.7%) | - | 24(33.3%) | 72(100%) |
| 7 | Glimepiride 2 mg | 47(65.3%) | - | - | - | 25(34.7%) | 72(100%) |
| 8 | Glimepiride 3 mg | 38(52.8%) | - | 3(4.2%) | - | 31(43.1%) | 72(100%) |
| 9 | Glimepiride 4 mg | 42(58.3%) | - | - | - | 30(41.7%) | 72(100%) |
| 10 | Glibenclamide 5 mg | - | - | 33(45.8%) | 1(1.4%) | 39(54.2%) | 71(98.6%) |
| 11 | Empagliflozin 10 mg | - | - | 1(1.4%) | - | 71(98.6%) | 72(100%) |
| 12 | Empagliflozin 25 mg | - | - | 3(4.2%) | 1(1.4%) | 69(95.8%) | 71(98.6%) |
| 13 | Dapagliflozin 5 mg | - | - | 14(19.4%) | - | 58(80.6%) | 72(100%) |
| 14 | Dapagliflozin 10 mg | - | - | 14(19.4%) | - | 58(80.6%) | 72(100%) |
| 15 | Linagliptin 5 mg | - | - | 2(2.8%) | - | 70(97.2%) | 72(100%) |
| 16 | Gliclazide 30 mg | - | - | 1(1.4%) | - | 71(98.6%) | 72(100%) |
| 17 | Gliclazide 60 mg | - | - | - | - | 72(100%) | 72(100%) |
| 18 | Empagliflozin 5 mg + Metformin 500 mg | 1(1.4%) | - | 13(18.1%) | - | 58(80.6%) | 72(100%) |
| 19 | Empagliflozin 5 mg + Metformin 850 mg | - | - | 16(22.2%) | - | 56(77.8%) | 72(100%) |
| 20 | Empagliflozin 12.5 mg + Metformin 850 mg | - | - | 8(11.1%) | - | 64(88.9%) | 72(100%) |
| 21 | Pioglitazone 15 mg + Metformin 500 mg | 3(4.2%) | - | - | - | 69(95.8%) | 72(100%) |
| 22 | Pioglitazone 15 mg + Metformin 850 mg | 2(2.8%) | - | - | - | 70(97.2%) | 72(100%) |
| 23 | Glimepiride 1 mg + Metformin 500 mg | 16(22.2%) | - | 15(20.8%) | - | 41(56.9%) | 72(100%) |
| 24 | Glimepiride 2 mg + Metformin 500 mg | 1(1.4%) | - | 29(40.3%) | - | 42(58.3%) | 72(100%) |
| 25 | Sitagliptin 50 mg + Metformin 500 mg | - | - | 36(50.0%) | - | 36(50.0%) | 72(100%) |
| 26 | Sitagliptin 50 mg + Metformin 1000 mg | - | - | 35(48.6%) | - | 37(51.4%) | 72(100%) |
| 27 | Glibenclamide 5 mg + Metformin 500 mg | 14(19.4%) | - | 15(20.8%) | - | 43(59.7%) | 72(100%) |
| 28 | Glibenclamide 5 mg + Metformin 500 mg | 4(5.6%) | - | - | - | 68(94.4%) | 72(100%) |
| 29 | Insulin NPH | - | 1(1.4%) | 8(11.1%) | 5(6.9%) | 66(91.7%) | 66(91.7%) |
| 30 | Insulin Regular | - | 2(2.8%) | 10(14.1%) | 21(29.2%) | 61(85.9%) | 49(68.1%) |
| 31 | Insulin Glargine | 1(1.4%) | - | - | - | 71(98.6%) | 72(100%) |
| 32 | Insulin Aspart | - | - | - | - | 72(100%) | 72(100%) |
| 33 | Insulin Mix | - | - | 7(9.7%) | 10(13.9%) | 65(90.3%) | 62(86.1%) |